Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.25 and traded as high as $9.00. Hemispherx BioPharma shares last traded at $6.70, with a volume of 7,639 shares.
Hemispherx BioPharma Trading Down 20.0%
The business has a 50-day simple moving average of $6.70 and a 200-day simple moving average of $6.25.
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Featured Articles
- Five stocks we like better than Hemispherx BioPharma
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- ServiceNow’s $7 Billion Gamble: Panic or Opportunity?
- Transportation Stocks Investing
- Dell and HP Are Raising Prices—And Investors Should Take Note
- What does consumer price index measure?
- Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
